Newsletter · · Ashutosh Agarwal

Drug Prices Fell But Not For The Reason You Think - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of August 22, 2026

How the sharpest healthcare policy podcasts covered the biggest drug-price drop in 60 years, Mark Cuban's biosimilars-not-the-IRA argument, the Medicare Advantage retreat, and the 340B rebate pilot, for the week of August 15 to 22, 2026.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of August 15–22, 2026: Drug Prices Fell But Not For The Reason You Think

Intro

The White House is taking a victory lap. Prescription drug prices just had their biggest year-over-year drop in more than 60 years, and the administration wants the credit. But the most interesting thing said in podcasts this week is that the people who actually move drugs for a living don't think the policy did most of the work. Mark Cuban, who now runs a real, growing pharmacy business, went on a major podcast and quietly took the wind out of the whole narrative, then spent twenty minutes explaining who really controls what you pay. Meanwhile, the health insurers are in full retreat from Medicare Advantage, obesity-drug prices are collapsing toward numbers that sounded insane a year ago, and a wonky new rebate rule is about to blow a hole in hospital finances. Here is what the week's podcasts actually said, who said it, and why it matters for the companies in this space.

(One housekeeping note on how to read this: throughout, I flag whether a speaker is an operator, someone who runs a company inside the system and has money on the line, or a pundit, a journalist, analyst, or commentator. Both are useful, but they are not the same thing.)

TL;DR

  • The drug-price drop was mostly biosimilars, not Medicare negotiation. Mark Cuban, an operator, says the Inflation Reduction Act's price negotiation on 10 drugs was "a bonus," but that cheap copycat versions of injectable blockbusters did the heavy lifting: Stelara fell from $128,000 a year to $365, Humira from $8,000 a month to about $400.
  • Health insurers are choosing profit over size in Medicare Advantage. Humana is dropping plans covering roughly 600,000 members and only hopes to win back 40%; UnitedHealthcare, Aetna, and Centene are all pulling back too. The mantra now is "margin over growth."
  • Obesity drugs are heading toward $40–50 a month, and the choke point is China. The Hims & Hers CEO says the only reason a GLP-1 shot isn't already that cheap is a lack of competition, not manufacturing. But a separate podcast warns the U.S. peptide supply runs through one Chinese company that has become "too big to ban."

What's new

1. Mark Cuban says biosimilars, not the IRA, cracked drug prices, and that the middlemen are the real problem. On Pivot, guest-hosting alongside Kara Swisher, Cost Plus Drugs co-founder Mark Cuban (operator) was asked to referee the credit fight between the Biden-era IRA and the Trump administration. His answer: both helped a little, but neither is the story. "With the IRA where you're negotiating for 10 different medications, that's a bonus," he said, adding that the law's cap on Medicare out-of-pocket costs, which he put at $2,100, was "great for patients" but "increased premiums, right? Because the insurance companies had to compensate for the cap." The real driver, he argued, was competition from biosimilars (he described them as "like a generic for an injectable drug"): "That dropped the price for Stelara from $128,000 a year to on cost plus, it's $365 plus shipping every couple months… For Umira, it went from $8,000 a month to like $400 a month, $450 a month on cost plus. And I think that drove it more than anything." Why it matters: the single loudest political claim in healthcare right now, "we brought drug prices down," is being gently contradicted by an operator with no reason to flatter either party. If biosimilar and generic competition is the real lever, the investment read-through runs to the companies that make copycats and the ones (PBMs, big insurers) whose pricing power that competition erodes. Pivot: "Mark Cuban on High Drug Prices, Taxing Billionaires, and 2028" (Aug 21, 2026)

2. Insurers are retreating from Medicare Advantage, and it's a policy-driven retreat. On the Becker's Healthcare Podcast, payer reporter Jakob Emerson (pundit) laid out a striking picture of the private Medicare market heading into fall enrollment. "It's margin over growth," he said. "Years past, Medicare Advantage has been all about growth, getting as many members as possible. Now it's about preserving those margins." The specifics: Humana "said itself that they're trying to get back to 3% by 2028, a profit margin" and is "pulling out of markets and dropping products that currently cover about 600,000 of their members," hoping to recapture only about 40% of them. He added that "UnitedHealthcare is also eyeing more market exits this year," "Aetna is cutting broker commissions," and "Centene is going to do another year of market exits" after leaving six states last year and pulling back from another three. The trigger is federal: "The insurance industry did not get the rate increase from CMS that it wanted this year." Seniors, he warned, will see "less options, certainly less large network options. So less PPO plans and more of the HMOs." Why it matters: this is the ground truth behind the managed-care selloff. When the biggest MA players openly guide to a 3% margin and shed hundreds of thousands of members on purpose, the sector is telling you cost trend and government rates have outrun the business model, for now. Becker's Healthcare Podcast: "Jakob Emerson on Medicare Advantage Pullbacks and SCAN's Costco Partnership" (Aug 21, 2026)

3. A new 340B "rebate pilot" is about to hit hospital cash flow, and it's bolted onto the Medicare negotiation list. On Achieving Health's Washington Watch, healthcare consultants from Forvis Mazars walked through a change that will fly under most investors' radar. 340B is the program that lets safety-net hospitals and clinics buy drugs at a steep discount. Starting January 1, 2027, HRSA is launching a pilot where drugmakers can flip that discount into an after-the-fact rebate: the hospital "would need to buy the drug first and then submit claims-level data to receive a rebate." Crucially, "the pilot is limited to… selected drugs included in CMS's Medicare drug price negotiation selected drug list" (so the two big drug-pricing regimes are now wired together) and "at least 30% of a covered entity's 340B drug purchasing may be subject to the rebate model." Manufacturers get "at least 45 days from dispense for data submission" and then must "either pay the rebate or issue a documented denial within 10 days." Why it matters: forcing hospitals to pay full price up front and wait for a rebate on roughly a third of their 340B spend is a working-capital hit and a new denial-management headache. The consultants said hospitals should "build out a rebate cycle that functions much like their revenue cycle." For anyone modeling nonprofit and safety-net hospital liquidity, this is a real 2027 line item. Achieving Health: "Washington Watch: CJR-X Finalized, Price Transparency & Affordability, 340B Rebate Pilot Advances" (Aug 19, 2026)

4. The Hims & Hers CEO says a $40–50 GLP-1 is coming, and blames the current price on missing competition. On Squawk Pod, Andrew Dudum (operator), CEO of Hims & Hers, made the most aggressive pricing forecast of the week. Reacting to Bank of America's Brian Moynihan saying the bank now spends "$200+ million a year on GLP-1s for its employees," Dudum argued the price will fall hard: "You can deliver GLP-1 therapies… at a cost probably closer to $40 to $50 with high quality… It's only because of competitive dynamics that it doesn't exist today. It is not because of manufacturing constraints or supply chain issues." He sees "5 or 6 new companies coming to market" (naming Kylera and Viking Therapeutics) and expects "probably by 2030, which is ultimately when semaglutide, Wegovy… goes off patent," GLP-1s "in the $40 to $50 a month range." He also flagged a brutal adherence problem: "70% of patients after 30 or 90 days were not on the medication any longer." Why it matters: Dudum is talking his own book (cheaper drugs are great for a consumer telehealth platform and terrible for branded-drug margins), so weigh it as an operator with an agenda. But his core claim, that competition (not cost) sets the price, is the bear case for Lilly and Novo pricing power stated out loud by someone who has already forced prices down once. Squawk Pod: "AI 'Genies' & Hims & Hers CEO Andrew Dudum 8/18/26" (Aug 18, 2026)

5. Hospitals are quietly getting a Medicare payment sweetener for surgery centers, while surgical volumes fall. On This Week in Surgery Centers, the hosts covered the bipartisan NO PAIN Act, which would protect how Medicare updates payments to ambulatory surgery centers (ASCs): keeping the more generous "hospital market basket" update (a trial that otherwise ends after 2026) and scrapping a budget-neutrality adjustment "that can reduce ASC payment rates as procedure volume grows." They paired it with second-quarter operator data: HCA reported "same facility outpatient surgeries across its broader network declined 3.4% during the quarter," while Tenet's ambulatory business grew net operating revenue 9.3% even as same-facility surgical cases fell about 1.2%, because "revenue per case… increased 6.3%" on higher-acuity work. They quoted HCA CEO Sam Hazen (operator, relayed) saying "the company's ASC division still achieved earnings growth during the first half of the year" with "surgery center volume… slightly higher and case acuity… increasing." Why it matters: the surgery-center story is acuity and mix, not raw volume: a center "can perform more cases without generating stronger financial results." For hospital investors, that reframes the soft outpatient-surgery prints as a mix shift rather than a demand collapse, and the NO PAIN Act is a modest reimbursement tailwind if it passes. This Week in Surgery Centers: "What the NO PAIN Act Means for ASCs" (Aug 18, 2026)

The debate: Did policy or competition bring drug prices down?

This was the live argument this week, and both sides showed up in the podcasts.

The case that competition (not government) did it. Cuban is the clearest voice here. He credits biosimilars first, and he is scathing about the middlemen (pharmacy benefit managers, or PBMs, the companies that decide which drugs your insurance covers) as the thing keeping prices high in the first place. His fix is almost mechanical: strip PBMs of their power over drug lists. "If you just say, made a law that said PBMs are no longer able to control formularies," he said, describing how PBMs allegedly tell drugmakers that dealing with Cost Plus will get them punished across "the 80 million people we cover." He praised a Josh Hawley and Elizabeth Warren "break up big medicine" bill but noted "not one single senator got behind them." Dudum reinforces the same logic from the obesity side: prices fall when new entrants show up, full stop. On the pharma-economics side, On The Pen explained why the drugmakers themselves are leaning into this: "both Lilly and Novo talking about making up for the lowering of prices of drugs by… expanding the volume," a deliberate trade of price for reach across "100 million people strong in the United States that could benefit."

The case that policy still matters. The government levers are real and, in places, growing. Cuban himself gives the administration credit on specific fronts: "he put some pressure on the GLP-1 guys… particularly within Medicare, where in certain cases, you can get it for $50 a month," and calls the IRA cap a genuine patient win even as it lifted premiums. The 340B rebate pilot and the expanding Medicare negotiation list (now the trigger for that pilot) show the policy machine reaching deeper into how drugs are priced and paid for, not retreating. And Emerson's MA reporting is a reminder that a single federal decision, CMS declining to give insurers the rate increase they wanted, reshaped an entire market's strategy in one year.

Where it nets out from the podcasts: the honest read is that competition did most of the recent price drop, but policy increasingly sets the rules of the game: who can compete, what gets negotiated, and how the discounts flow. The two are not really rivals; they are the numerator and denominator.

The names in play

This was a policy-and-pricing week more than a single-stock week, but several names came up with real numbers attached:

  • Eli Lilly (LLY). Two podcasts put hard figures on the quarter. DHUnplugged cited Lilly's diabetes GLP-1 Mounjaro at "$9.94 billion" and its obesity twin Zepbound at "$4.93 billion" ("exactly the same drug," one marketed for diabetes, one for weight loss) with the company having "raised their revenue guidance" and "definitely leading over Novo Nordisk." Telltales (note: this is an AI-generated show, so treat its figures as second-hand) reported "second quarter revenue of about $23 billion, up 48%, beating consensus by 11%," adjusted earnings "of $838 against $658 expected," full-year guidance raised "to $35.50 to $36.50," the oral GLP-1 winning "its first European approval in the UK, with weekly prescriptions at a new high of about 29,000," and Lilly agreeing "to acquire three vaccine biotechs… for up to $3.8 billion," which it framed as "a company spending obesity money on vaccines."
  • Humana (HUM), UnitedHealth (UNH), Centene (CNC), Aetna/CVS (CVS). The MA pullback names above, per Emerson: Humana guiding to a 3% margin by 2028 and shedding ~600,000 members' worth of products; UNH eyeing more exits; Centene exiting three more states; Aetna cutting broker pay.
  • Hims & Hers (HIMS). Dudum's whole appearance was a bet that cheap, competitive GLP-1s plus data-driven "concierge" care is the future, while acknowledging an ongoing FTC lawsuit over subscription and marketing practices.
  • HCA (HCA), Tenet (THC). The surgery-center acuity story above.
  • SCAN (private) + Costco (COST). A wildcard: nonprofit insurer SCAN, led by Dr. Sachin Jain, is launching co-branded Medicare Advantage plans with Costco in two states plus a Medicare supplement plan in a third, in a market of "roughly 5 million potential Medicare enrollees." Emerson stressed "Costco is not going to be underwriting anything here… Scan is ultimately the insurance company," more a licensing-and-storefront deal than a risk-bearing one. Notably, SCAN "broke into the top 10 of the largest MA plans" after adding "over 120,000 members," a rare growth story in a week of retreat.

Read-throughs

  • PBMs (pharmacy middlemen). Cuban's entire thesis is an attack on PBM formulary control, and he claims the government can't even see their prices, citing Elizabeth Warren being stonewalled by Express Scripts over what it charges the military's Tricare program: "That's proprietary information." Regulatory and competitive pressure on PBM economics is the recurring bear theme.
  • Biosimilars / generics. The clear winners of the week's narrative. If competition, not negotiation, is what actually lowers prices, the copycat makers and low-cost distributors (Cost Plus among them) are structurally advantaged, and a threat to branded pricing.
  • Ex-US / supply chain. On The Pen delivered the week's most underappreciated risk: U.S. GLP-1 supply leans heavily on China. It highlighted a Bloomberg framing that WuXi AppTech has become "too big to ban" and holds a "GLP-1 chokehold," because so much peptide manufacturing ("raw materials… chemical intermediates… peptide fragments… peptide synthesis") runs through it. Washington wants less China dependence; the pharma reality is that the capacity is there. Those two goals "may sometimes… be pulling against each other."
  • Medicaid / exchange insurers. On Becker's Healthcare, CountyCare's Crissy Turino (operator) described the coverage cliff from new Medicaid work requirements: "about 77%… would already qualify for some kind of exemption. But just due to… the bureaucratic nature and the additional administrative requirements… many of them will not get through that process." Translation: enrollment losses driven by paperwork, not eligibility, a headwind for Medicaid-heavy insurers and safety-net systems.
  • Optum-style services / care management. On Health Care Rounds, Omada Health president Wei-Li Shao (operator, ex-Lilly) made the case that wrapping services around GLP-1s is where the money and the health outcomes are. His striking pricing map: as of July 1, "Medicare recipients are paying $50 out of pocket," cash pay is "maybe $250, maximum $300… from where it was $1,300 a month," "but the commercially insured employer market is still paying a significantly higher price." He also flagged real clinical risk that creates a services opportunity: up to a third of weight lost is muscle, and a Wall Street Journal look at 400,000 patients found "one in five… were lacking significantly micro and macronutrients."
  • Hospitals. Beyond the surgery-center acuity story, the 340B rebate pilot is the sleeper hospital risk for 2027, and Experts InSight flagged another: the proposed 2027 Medicare physician fee schedule lets a temporary 2.5% bump expire and cuts the conversion factor a further 1.68%, with ophthalmology as a specialty facing an estimated ~4% cut driven by "practice expense" changes. Physician-payment pressure is a slow bleed for doctor-heavy and outpatient businesses.
  • GLP-1 exposure (the demand side). DHUnplugged offered a fun tell on the second-order effects: part of McDonald's soft sales is "there's a lot more people on peptides." The obesity-drug wave is now showing up as a headwind in consumer names, not just a tailwind in pharma.

What changed

  • The MA retreat got more concrete. Humana's explicit 3%-by-2028 margin target and ~600,000-member product drop, plus fresh reports of Centene exiting three more states and Aetna cutting broker commissions, moved this from "insurers are cautious" to named, quantified pullbacks heading into the fall enrollment season.
  • The 340B rebate pilot now has a hard date and a scope. January 1, 2027; tied to the Medicare negotiation drug list; roughly 30%+ of covered-entity 340B purchasing affected; and (an improvement over the earlier proposal) a formal denial-and-appeals process.
  • Enforcement, not just pricing, is now part of the drug story. BioSpace reported Lilly has sued six U.S. entities and "referred more than 200 other players to U.S. authorities," reporting "14,000 websites, social media posts, advertisements, online listings" across "100 countries" over black-market sales of its not-yet-launched obesity drug retatrutide, calling it "an urgent public health crisis." Fighting counterfeiters of a product you can't even buy yet is, as one host put it, "its own kind of demand data."